Literature DB >> 20613744

The inverse of immunity.

Elie Dolgin.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20613744     DOI： 10.1038/nm0710-740

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.

Authors:  William H Robinson; Paulo Fontoura; Byung J Lee; Henry E Neuman de Vegvar; Jennifer Tom; Rosetta Pedotti; Carla D DiGennaro; Dennis J Mitchell; Derek Fong; Peggy P-K Ho; Pedro J Ruiz; Emanual Maverakis; David B Stevens; Claude C A Bernard; Roland Martin; Vijay K Kuchroo; Johannes M van Noort; Claude P Genain; Sandra Amor; Tomas Olsson; Paul J Utz; Hideki Garren; Lawrence Steinman
Journal:  Nat Biotechnol       Date:  2003-08-10       Impact factor: 54.908

2.  Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.

Authors:  K G Warren; I Catz; L Z Ferenczi; M J Krantz
Journal:  Eur J Neurol       Date:  2006-08       Impact factor: 6.089

3.  Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.

Authors:  B Metzler; D C Wraith
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

4.  Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity.

Authors:  L Steinman
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

5.  Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions.

Authors:  Kevin C O'Connor; Tanuja Chitnis; Diane E Griffin; Sucheep Piyasirisilp; Amit Bar-Or; Samia Khoury; Kai W Wucherpfennig; David A Hafler
Journal:  J Neuroimmunol       Date:  2003-03       Impact factor: 3.478

6.  Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides.

Authors:  M K Kennedy; L J Tan; M C Dal Canto; V K Tuohy; Z J Lu; J L Trotter; S D Miller
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

7.  T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.

Authors:  K Ota; M Matsui; E L Milford; G A Mackin; H L Weiner; D A Hafler
Journal:  Nature       Date:  1990-07-12       Impact factor: 49.962

8.  Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis.

Authors:  K G Warren; I Catz
Journal:  J Neuroimmunol       Date:  1993-03       Impact factor: 3.478

9.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

Authors:  H L Weiner; G A Mackin; M Matsui; E J Orav; S J Khoury; D M Dawson; D A Hafler
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

10.  Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

Authors:  Hideki Garren; William H Robinson; Eva Krasulová; Eva Havrdová; Congor Nadj; Krzysztof Selmaj; Jacek Losy; Ilinka Nadj; Ernst-Wilhelm Radue; Brian A Kidd; Jill Gianettoni; Karen Tersini; Paul J Utz; Frank Valone; Lawrence Steinman
Journal:  Ann Neurol       Date:  2008-05       Impact factor: 10.422
View more
  10 in total

1.  Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.

Authors:  Joshua O Sestak; Amir Fakhari; Ahmed H Badawi; Teruna J Siahaan; Cory Berkland
Journal:  AAPS J       Date:  2014-09-06       Impact factor: 4.009

Review 2.  Engineering synthetic vaccines using cues from natural immunity.

Authors:  Darrell J Irvine; Melody A Swartz; Gregory L Szeto
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

Review 3.  The immunopathophysiology of multiple sclerosis.

Authors:  Gregory F Wu; Enrique Alvarez
Journal:  Neurol Clin       Date:  2011-05       Impact factor: 3.806

4.  Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.

Authors:  Jennifer Pfeil; Mario Simonetti; Uta Lauer; Bianca von Thülen; Pawel Durek; Christina Poulsen; Justyna Pawlowska; Matthias Kröger; Ralf Krähmer; Frank Leenders; Ute Hoffmann; Alf Hamann
Journal:  Ther Adv Chronic Dis       Date:  2021-08-12       Impact factor: 5.091

5.  Optimization of current and future therapy for autoimmune diseases.

Authors:  Lawrence Steinman; Joan T Merrill; Iain B McInnes; Mark Peakman
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

6.  Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis.

Authors:  Joshua O Sestak; Bradley P Sullivan; Sharadvi Thati; Laura Northrup; Brittany Hartwell; Lorena Antunez; M Laird Forrest; Charlotte M Vines; Teruna J Siahaan; Cory Berkland
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-09       Impact factor: 6.698

Review 7.  Restoring immune tolerance in neuromyelitis optica: Part I.

Authors:  Larry Steinman; Amit Bar-Or; Jacinta M Behne; Daniel Benitez-Ribas; Peter S Chin; Michael Clare-Salzler; Donald Healey; James I Kim; David M Kranz; Andreas Lutterotti; Roland Martin; Sven Schippling; Pablo Villoslada; Cheng-Hong Wei; Howard L Weiner; Scott S Zamvil; Michael R Yeaman; Terry J Smith
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-09-07

8.  Tolerogenic Immunomodulation by PEGylated Antigenic Peptides.

Authors:  Jennifer Pfeil; Mario Simonetti; Uta Lauer; Rudolf Volkmer; Bianca von Thülen; Pawel Durek; Ralf Krähmer; Frank Leenders; Alf Hamann; Ute Hoffmann
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 9.  Reestablish immune tolerance in rheumatoid arthritis.

Authors:  Ziqiang Shuai; Shuang Zheng; Kang Wang; Jian Wang; Patrick S C Leung; Bin Xu
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

Review 10.  Review of Mouse Models of Graves' Disease and Orbitopathy-Novel Treatment by Induction of Tolerance.

Authors:  Martin Ungerer; Julia Faßbender; Zhongmin Li; Götz Münch; Hans-Peter Holthoff
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.